Cytosorbents (NASDAQ:CTSO) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s Why

Shares of Cytosorbents Co. (NASDAQ:CTSO) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.04 and traded as high as $1.05. Cytosorbents shares last traded at $1.00, with a volume of 44,234 shares traded.

Wall Street Analysts Forecast Growth

CTSO has been the subject of a number of recent analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a report on Monday, January 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a report on Monday, November 11th. Finally, StockNews.com began coverage on shares of Cytosorbents in a research report on Wednesday. They issued a “hold” rating on the stock. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Trading Down 3.8 %

The stock has a market capitalization of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.58. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a fifty day moving average of $0.95 and a two-hundred day moving average of $1.04.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The company had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. During the same period last year, the company earned ($0.21) earnings per share. On average, research analysts expect that Cytosorbents Co. will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. Sargent Investment Group LLC boosted its holdings in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Finally, Atomi Financial Group Inc. acquired a new stake in Cytosorbents during the third quarter worth about $51,000. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.